Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Swiss Group for Clinical Cancer Research"
|Adjuvant Aspirin Treatment for Colon Cancer Patients
|Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
|Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
|Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
|LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
|SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
|1st Line Durvalumab in PS 2 NSCLC Patients
|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
|Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
|Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
|Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
|TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
|Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
|Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
|Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.
|Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
|Activity Program During Aromatase Inhibitor Therapy
|Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
|CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
|Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
|Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
|Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
|Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
|Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
|Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
|VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
|ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
|Therapy De-escalation in Seminoma Stage IIA/B
|Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
|Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
|Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
|Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy
|NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
|Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
|Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
|Prostate Cancer Biobank
|SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
|Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
|Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
|Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
|Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
|Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
|Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
|Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
|Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
|Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
|Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
|Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
|Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer